Cushing Triad, also known as the Cushing reflex, is a medical condition characterized by a combination of three signs: hypertension, bradycardia, and an irregular respiratory rate. It is most commonly associated with increased intracranial pressure (ICP) due to a variety of causes, including traumatic brain injury, brain tumors, hydrocephalus, and intracranial hematomas. The triad is named after Harvey Cushing, an American neurosurgeon who first described the condition in 1932. This article provides a comprehensive overview of Cushing Triad, including its diagnosis and treatment.
The diagnosis of Cushing Triad is based on the presence of three clinical signs: hypertension, bradycardia, and an irregular respiratory rate. Hypertension is defined as a systolic blood pressure greater than 150 mmHg and/or a diastolic blood pressure greater than 90 mmHg. Bradycardia is defined as a heart rate less than 60 beats per minute. An irregular respiratory rate is defined as an increase in the respiratory rate of more than 10 breaths per minute or a decrease in the respiratory rate of more than 10 breaths per minute. The diagnosis of Cushing Triad is usually made based on the presence of these three clinical signs. However, in some cases, additional tests may be necessary to confirm the diagnosis. These tests may include computed tomography (CT) or magnetic resonance imaging (MRI) scans of the head, a lumbar puncture to measure the intracranial pressure, and/or an electroencephalogram (EEG) to measure brain activity.
Cushing Triad is most commonly associated with increased intracranial pressure (ICP) due to a variety of causes, including traumatic brain injury, brain tumors, hydrocephalus, and intracranial hematomas. Other causes of Cushing Triad include meningitis, subarachnoid hemorrhage, and intracranial hypertension due to drug toxicity or metabolic disorders.
The treatment of Cushing Triad is aimed at reducing the underlying cause of the increased intracranial pressure. This may include surgery to remove the tumor or hematoma, or to relieve pressure on the brain. Other treatments may include medications to reduce the pressure, such as diuretics, corticosteroids, and osmotic agents. In some cases, treatment may also include the use of a ventriculostomy, which is a procedure in which a small hole is made in the skull to relieve pressure on the brain. Finally, in some cases, treatment may include the use of a shunt, which is a device that is surgically implanted to divert excess cerebrospinal fluid away from the brain.
Cushing Triad is a medical condition characterized by a combination of three signs: hypertension, bradycardia, and an irregular respiratory rate. It is most commonly associated with increased intracranial pressure due to a variety of causes, including traumatic brain injury, brain tumors, hydrocephalus, and intracranial hematomas. The diagnosis of Cushing Triad is based on the presence of these three clinical signs, and additional tests may be necessary to confirm the diagnosis. Treatment of Cushing Triad is aimed at reducing the underlying cause of the increased intracranial pressure, and may include surgery, medications, a ventriculostomy, or a shunt.
1.
Remote monitoring can improve recovery from cancer surgery
2.
Intractable cancers may respond better to treatment when using new radiation and high-performance computing.
3.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
4.
Conditional EU Nod for Weekly Pill in Pediatric Glioma
5.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
1.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
5.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation